ivonescimab   Click here for help

GtoPdb Ligand ID: 13396

Synonyms: AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
Approved drug Immunopharmacology Ligand
ivonescimab is an approved drug (China (2024))
Compound class: Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It was designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [5].
No information available.
Summary of Clinical Use Click here for help
Ivonescimab (SMT112) was progressed as a clinical candidate for the treatment of advanced solid tumours. Firts international approval was granted by the Chinese NMPA in May 2024 (in combination with pemetrexed and carboplatin) [1], for the treatment of EGFR-mutated locally advanced/metastatic non-squamous NSCLC that has progressed after tyrosine kinase inhibitor therapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04047290 A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1 Interventional Akeso 2
NCT05184712 Phase 3 Clinical Study of AK112 for NSCLC Patients Phase 3 Interventional Summit Therapeutics 3
NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC Phase 2 Interventional Akeso 4